Publications

2019

301.
Shreberk-Shaked M. & Oren M. (2019). New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?.  Molecular Oncology. 13:(6)1335-1341.  Abstract
300.
Hooda J., Novak M., Salomon M. P., Matsuba C., Ramos R. I., MacDuffie E., Song M., Hirsch M. S., Lester J., Parkash V., Karlan B. Y., Oren M., Hoon D. S. & Drapkin R. (2019). Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.  Cancer Research. 79:(4)760-772.  Abstract

2018

299.
Furth N., Pateras I. S., Rotkopf R., Vlachou V., Rivkin I., Schmitt I., Bakaev D., Gershoni A., Ainbinder E., Leshkowitz D., Johnson R. L., Gorgoulis V. G., Oren M. & Aylon Y. (2018). LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state.  Life science alliance. 1:(5)  Abstract
298.
Minzel W., Venkatachalam A., Fink A., Hung E., Brachya G., Burstain I., Shaham M., Rivlin A., Omer I., Zinger A., Elias S., Winter E., Erdman P. E., Sullivan R. W., Fung L., Mercurio F., Li D., Vacca J., Kaushansky N., Shlush L., Oren M., Levine R., Pikarsky E., Snir-Alkalay I. & Ben-Neriah Y. (2018). Small Molecules Co-targeting CKI alpha and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.  Cell. 175:(1)171-+.  Abstract
297.
Kotler E., Segal E. & Oren M. (2018). Functional characterization of the p53 "mutome".  Molecular & cellular oncology. 5:(6)  Abstract
296.
Kotler E., Shani O., Goldfeld G., Lotan-Pompan M., Tarcic O., Gershoni A., Hopf T. A., Marks D. S., Oren M. & Segal E. (2018). A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.  Molecular Cell. 71:(1)178-190.e8.  Abstract
295.
Arandkar S., Furth N., Elisha Y., Belugali Nataraj N., van der Kuip H., Yarden Y., Aulitzky W., Ulitsky I., Geiger B. & Oren M. (2018). Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 115:(25)6410-6415.  Abstract
294.
, Jethwa A., Slabicki M., Huellein J., Jentzsch M., Dala V., Rabe S., Wagner L., Walther T., Klapper W., Bohnenberger H., Rettel M., Lu J., Smits A. H., Stein F., Savitski M. M., Huber W., Aylon Y., Oren M. & Zenz T. (2018). TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.  Blood. 131:(25)2789-2802.  Abstract
293.
Ghannam-Shahbari D., Jacob E., Kakun R. R., Wasserman T., Korsensky L., Sternfeld O., Kagan J., Bublik D. R., Aviel-Ronen S., Levanon K., Sabo E., Larisch S., Oren M., Hershkovitz D. & Perets R. (2018). PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.  Oncogene. 37:(17)2213-2224.  Abstract
292.
, Galluzzi L., Vitale I., Aaronson S. A., Abrams J. M., Adam D., Agostinis P., Alnemri E. S., Altucci L., Amelio I., Andrews D. W., Annicchiarico-Petruzzelli M., Antonov A. V., Arama E., Baehrecke E. H., Barlev N. A., Bazan N. G., Bernassola F., Bertrand M. J. M., Bianchi K., Blagosklonny M. V., Blomgren K., Borner C., Boya P., Brenner C., Campanella M., Candi E., Carmona-Gutierrez D., Cecconi F., Chan F. K. -., Chandel N. S., Cheng E. H., Chipuk J. E., Cidlowski J. A., Ciechanover A., Cohen G. M., Conrad M., Cubillos-Ruiz J. R., Czabotar P. E., D'Angiolella V., Dawson T. M., Dawson V. L., De laurenzi V., De Maria R., Debatin K., DeBerardinis R. J., Deshmukh M., Gross A., Kimchi A., Oren M. & Wallach D. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.  Cell Death Differ. 25:(3)486-541.  Abstract
291.
Solomon H., Dinowitz N., Pateras I. S., Cooks T., Shetzer Y., Molchadsky A., Charni M., Rabani S., Koifman G., Tarcic O., Porat Z., Kogan-Sakin I., Goldfinger N., Oren M., Harris C. C., Gorgoulis V. G. & Rotter V. (2018). Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.  Oncogene. 37:(12)1669-1684.  Abstract

2017

290.
Enuka Y., Feldman M. E., Chowdhury A., Srivastava S., Lindzen M., Sas-Chen A., Massart R., Cheishvili D., Suderman M. J., Zaltsman Y., Mazza C. A., Shukla K., Koerner C., Furth N., Lauriola M., Oren M., Wiemann S., Szyf M. & Yarden Y. (2017). Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone.  Nucleic Acids Research. 45:(22)12681–12699.  Abstract
289.
Aylon Y. & Oren M. (2017). Tumor Suppression by p53: Bring in the Hippo!.  Cancer Cell. 32:(4)397-399.  Abstract
288.
Spolverini A., Fuchs G., Bublik D. R. & Oren M. (2017). let-7b and let-7c microRNAs promote histone H2B ubiquitylation and inhibit cell migration by targeting multiple components of the H2B deubiquitylation machinery.  Oncogene. 36:(42)5819-5828.  Abstract
287.
Tovy A., Spiro A., McCarthy R., Shipony Z., Aylon Y., Allton K., Ainbinder E., Furth N., Tanay A., Barton M. & Oren M. (2017). p53 is essential for DNA methylation homeostasis in naive embryonic stem cells, and its loss promotes clonal heterogeneity.  GENES & DEVELOPMENT. 31:(10)959-972.  Abstract
286.
Tarcic O., Granit R. Z., Pateras I. S., Masury H., Maly B., Zwang Y., Yarden Y., Gorgoulis V. G., Pikarsky E., Ben-Porath I. & Oren M. (2017). RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer.  Cell Death and Differentiation. 24:(4)694-704.  Abstract
285.
Bublik D. R., Bursac S., Sheffer M., Orsolic I., Shalit T., Tarcic O., Kotler E., Mouhadeb O., Hoffman Y., Fuchs G., Levin Y., Volarevic S. & Oren M. (2017). Regulatory module involving FGF13, miR-504, and p53 regulates ribosomal biogenesis and supports cancer cell survival.  Proceedings of the National Academy of Sciences of the United States of America. 114:(4)E496-E505.  Abstract

2016

284.
Oren M. & Kotler E. (2016). p53 mutations promote proteasomal activity.  Nature Cell Biology. 18:(8)833-835.  Abstract
283.
Stock K., Estrada M. F., Vidic S., Gjerde K., Rudisch A., Santo V. E., Barbier M., Blom S., Arundkar S. C., Selvam I., Osswald A., Stein Y., Gruenewald S., Brito C., van Weerden W. W., Rotter V., Boghaert E., Oren M., Sommergruber W., Chong Y., de Hoogt H. R. & Graeser R. (2016). Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.  Scientific Reports. 6.  Abstract
282.
Aylon Y. & Oren M. (2016). The Hippo pathway, p53 and cholesterol.  Cell cycle (Georgetown, Tex.). 15:(17)2248-55.  Abstract
281.
Orsolic I., Jurada D., Pullen N., Oren M., Eliopoulos A. G. & Volarevic S. (2016). The relationship between the nucleolus and cancer: Current evidence and emerging paradigms.  Seminars in Cancer Biology. 37-38:36-50.  Abstract
280.
Oren M., Tal P. & Rotter V. (2016). Targeting mutant p53 for cancer therapy.  AGING-US. 8:(6)1159-1160.
279.
Aylon Y., Gershoni A., Rotkopf R., Biton I. E., Porat Z., Koh A. P., Sun X., Lee Y., Fiel M., Hoshida Y., Friedman S. L., Johnson R. L. & Oren M. (2016). The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.  GENES & DEVELOPMENT. 30:(7)786-97.  Abstract
278.
Yaeger R., Shah M. A., Miller V. A., Kelsen J. R., Wang K., Heins Z. J., Ross J. S., He Y., Sanford E., Yantiss R. K., Balasubramanian S., Stephens P. J., Schultz N., Oren M., Tang L. & Kelsen D. (2016). Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.  Gastroenterology. 151:(2)278-287.e6.  Abstract
277.
Tal P., Eizenberger S., Cohen E., Goldfinger N., Pietrokovski S., Oren M. & Rotter V. (2016). Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.  Oncotarget. 7:(11)11817-11837.  Abstract
276.
Hoffman Y., Bublik D. R., Ugalde A. P., Elkon R., Biniashvili T., Agami R., Oren M. & Pilpel Y. (2016). 3 ' UTR Shortening Potentiates MicroRNA-Based Repression of Pro-differentiation Genes in Proliferating Human Cells.  PLoS Genetics. 260-262.  Abstract
275.
Tarcic O., Pateras I. S., Cooks T., Shema E., Kanterman J., Ashkenazi H., Boocholez H., Hubert A., Rotkopf R., Baniyash M., Pikarsky E., Gorgoulis V. G. & Oren M. (2016). RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer.  Cell Reports. 14:(6)1462-1476.  Abstract
274.
Oren M., Furth N., Ben-Moshe N. B., Porat Z., Domany E., Pozniak Y., Geiger T. & Aylon Y. (2016). Tumor suppressor crosstalk: Modulation of p53 activity by the Hippo pathway.  Cancer Research. 76:(2016)

2015

273.
Furth N., Bossel Ben-Moshe B. N., Pozniak Y., Porat Z., Geiger T., Domany E., Aylon Y. & Oren M. (2015). Down-regulation of LATS kinases alters p53 to promote cell migration.  GENES & DEVELOPMENT. 29:(22)2325-30.  Abstract
272.
Harel S., Ben-Moshe N., Aylon Y., Bublik D., Moskovits N., Toperoff G., Azaiza D., Biagoni F., Fuchs G., Wilder S., Hellman A., Blandino G., Domany E. & Oren M. (2015). Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.  Cell Death and Differentiation. 22:(8)1328-1340.  Abstract
271.
Fuchs G., Voichek Y., Rabani M., Benjamin S., Gilad S., Amit I. & Oren M. (2015). Simultaneous measurement of genome-wide transcription elongation speeds and rates of RNA polymerase II transition into active elongation with 4sUDRB-seq.  Nature Protocols. 10:(4)605-618.  Abstract
270.
Golomb L., Sagiv A., Pateras I., Maly A., Krizhanovsky V., Gorgoulis V., Oren M. & Ben-Yehuda A. (2015). Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy.  Cell Death and Differentiation. 22:(11)1764-1774.  Abstract
269.
Oren M. & Arundkar S. C. (2015). P53-dependent non-coding RNA networks in chronic lymphocytic leukemia.  Leukemia. 29:(10)2015-2023.  Abstract

2014

268.
Lasry A., Aran D., Zinger A., Hamza H., Kadosh E., Elyada E., Pribluda A., Hellman A., Oren M., Pikarsky E. & Ben-Neriah Y. (2014). Parainflammation in cancer.  Cytokine. 70:(1)22-22.  Abstract
267.
Fuchs G., Hollander D., Voichek Y., Ast G. & Oren M. (2014). Cotranscriptional histone H2B monoubiquitylation is tightly coupled with RNA polymerase II elongation rate.  Genome Research. 24:(10)1572-1583.  Abstract
266.
Fuchs G. & Oren M. (2014). Writing and reading H2B monoubiquitylation.  Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms. 1839:(8)694-701.  Abstract
265.
Golomb L., Volarevic S. & Oren M. (2014). p53 and ribosome biogenesis stress: The essentials.  FEBS Letters. 588:(16)2571-2579.  Abstract
264.
Cooks T., Harris C. & Oren M. (2014). Caught in the cross fire: p53 in inflammation.  Carcinogenesis. 35:(8)1680-1690.  Abstract
263.
Weilbacher A., Gutekunst M., Oren M., Aulitzky W. E. & van der Kuip d. K. H. (2014). RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.  Cell Death & Disease. 5.  Abstract
262.
Hoffman Y., Pilpel Y. & Oren M. (2014). microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.  Journal of Molecular Cell Biology. 6:(3)192-197.  Abstract
261.
Aylon Y., Sarver A., Tovy A., Ainbinder E. & Oren M. (2014). Lats2 is critical for the pluripotency and proper differentiation of stem cells.  Cell Death and Differentiation. 21:(4)624-633.  Abstract
260.
Shtivelman E., Davies M. A., Hwu P., Yang J., Lotem M., Oren M., Flaherty K. T. & Fisher D. E. (2014). Pathways and therapeutic targets in melanoma.  Oncotarget. 5:(7)1701-1752.  Abstract
259.
Hoffman Y., Bublik D. R., Pilpel Y. & Oren M. (2014). miR-661 downregulates both Mdm2 and Mdm4 to activate p53.  Cell Death and Differentiation. 21:(2)302-309.  Abstract
258.
Weingarten-Gabbay S., Khan D., Liberman N., Yoffe Y., Bialik S., Das S., Oren M. & Kimchi A. (2014). The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA.  Oncogene. 33:(5)611-618.  Abstract
257.
Fuchs G., Voichek Y., Benjamin S., Gilad S., Amit I. & Oren M. (2014). 4sUDRB-seq: measuring genomewide transcriptional elongation rates and initiation frequencies within cells.  GENOME BIOLOGY. 15:(5)  Abstract

2013

256.
Fausti F., Di Agostino A. S., Cioce M., Bielli P., Sette C., Pandolfi P. P., Oren M., Sudol M., Strano S. & Blandino G. (2013). ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence.  Cell Death and Differentiation. 20:(11)1498-1509.  Abstract
255.
Golomb L. & Oren M. (2013). In the race for protection, ARF comes second.  Cell Death and Differentiation. 20:(11)1442-1443.
254.
Suzuki H., Yabuta N., Okada N., Torigata K., Aylon Y., Oren M. & Nojima H. (2013). Lats2 phosphorylates p21/CDKN1A after UV irradiation and regulates apoptosis.  Journal of Cell Science. 126:(19)4358-4368.  Abstract
253.
Shema E., Nikolov M., Haj-Yahya M., Siman P., Allemand E., Yamaguchi Y., Muchardt C., Urlaub H., Brik A., Oren M. & Fischle W. (2013). Systematic Identification of Proteins Binding to Chromatin-Embedded Ubiquitylated H2B Reveals Recruitment of SWI/SNF to Regulate Transcription.  Cell Reports. 4:(3)601-608.  Abstract
252.
Pribluda A., Elyada E., Wiener Z., Hamza H., Goldstein R. E., Biton M., Burstain I., Morgenstern Y., Brachya G., Billauer H., Biton S., Snir-Alkalay I., Vucic D., Schlereth K., Mernberger M., Stiewe T., Oren M., Alitalo K. & Pikarsky E. (2013). A Senescence-Inflammatory Switch from Cancer-Inhibitory to Cancer-Promoting Mechanism.  Cancer Cell. 24:(2)242-256.  Abstract
251.
Cooks T., Pateras I. S., Tarcic O., Solomon H., Schetter A. J., Wilder S., Lozano G., Pikarsky E., Forshew T., Rozenfeld N., Harpaz N., Itzkowitz S., Harris C. C., Rotter V., Gorgoulis V. G. & Oren M. (2013). Mutant p53 Prolongs NF-kappa B Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer.  Cancer Cell. 23:(5)634-646.  Abstract
250.
Hoffman Y., Dahary D., Bublik D. R., Oren M. & Pilpel Y. (2013). The majority of endogenous microRNA targets within Alu elements avoid the microRNA machinery.  Bioinformatics. 29:(7)894-902.  Abstract
249.
Gutekunst M., Mueller T., Weilbacher A., Dengler M. A., Oren M., Aulitzky W. E. & van der Kuip d. K. H. (2013). Testicular germ cell tumors are hypersensitive to p53 activation based on their Oct-4/Noxa-mediated cellular context rather than on differential p53 activity.  .
248.
Gutekunst M., Mueller T., Weilbacher A., Dengler M. A., Bedke J., Kruck S., Oren M., Aulitzky W. E. & van der Kuip d. K. H. (2013). Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4.  Cancer Research. 73:(5)1460-1469.  Abstract

2012

247.
Hornung G., Bar-Ziv R., Rosin D., Tokuriki N., Tawfik D., Oren M. & Barkai N. (2012). Noise-mean relationship in mutated promoters.  Genome Research. 22:(12)2409-2417.  Abstract
246.
Bursac S., Brdovcak M. C., Pfannkuchen M., Orsolic I., Golomb L., Zhu Y., Katz C., Daftuar L., Grabusic K., Vukelic I., Filic V., Oren M., Prives C. & Volarevic S. (2012). Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress.  Proceedings of the National Academy of Sciences of the United States of America. 109:(50)20467-20472.  Abstract
245.
Schmid J. O., Dong M., Haubeiss S., Friedel G., Bode S., Grabner A., Ott G., Muerdter T. E., Oren M., Aulitzky W. E. & van der Kuip d. K. H. (2012). Cancer Cells Cue the p53 Response of Cancer-Associated Fibroblasts to Cisplatin.  Cancer Research. 72:(22)5824-5832.  Abstract
244.
Fuchs G., Shema E., Vesterman R., Kotler E., Wolchinsky Z., Wilder S., Golomb L., Pribluda A., Zhang F., Haj-Yahya M., Feldmesser E., Brik A., Yu X., Hanna J., Aberdam D., Domany E. & Oren M. (2012). RNF20 and USP44 Regulate Stem Cell Differentiation by Modulating H2B Monoubiquitylation.  Molecular Cell. 46:(5)662-673.  Abstract
243.
Hornung G., Oren M. & Barkai N. (2012). Nucleosome Organization Affects the Sensitivity of Gene Expression to Promoter Mutations.  Molecular Cell. 46:(3)362-368.  Abstract
242.
Bublik D. R. & Oren M. (2012). Get your fingers out of p53's way!.  EMBO Reports. 13:(4)282-283.
241.
Zwang Y., Oren M. & Yarden Y. (2012). Consistency Test of the Cell Cycle: Roles for p53 and EGR1.  Cancer Research. 72:(5)1051-1054.  Abstract
240.
Blandino G., Deppert W., Hainaut P., Levine A., Lozano G., Olivier M., Rotter V., Wiman K. & Oren M. (2012). Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop.  Cell Death and Differentiation. 19:(1)180-183.
239.
Golomb L., Bublik D. R., Wilder S., Nevo R., Kiss V., Grabusic K., Volarevic S. & Oren M. (2012). Importin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis.  Molecular Cell. 45:(2)222-232.  Abstract
238.
Haj-Yahya M., Eltarteer N., Ohayon S., Shema E., Kotler E., Oren M. & Brik A. (2012). N-Methylation of Isopeptide Bond as a Strategy to Resist Deubiquitinases.  ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 51:(46)11535-11539.

2011

237.
Shiloh Y., Shema E., Moyal L. & Oren M. (2011). RNF20-RNF40: A ubiquitin-driven link between gene expression and the DNA damage response.  FEBS Letters. 585:(18)2795-2802.  Abstract
236.
Golomb L. & Oren M. (2011). DePICTing p53 Activation: A New Nucleolar Link to Cancer.  Cancer Cell. 20:(3)283-284.  Abstract
235.
Furth N. & Oren M. (2011). An Aurora A-Lats-Aurora B axis ensures proper chromosome segregation.  Cell Cycle. 10:(18)3054-3055.
234.
Aylon Y. & Oren M. (2011). p53: Guardian of ploidy.  Molecular Oncology. 5:(4)315-323.  Abstract
233.
Tarocchi M., Hannivoort R., Hoshida Y., Lee U. E., Vetter D., Narla G., Villanueva A., Oren M., Llovet J. M. & Friedman S. L. (2011). Carcinogen-Induced Hepatic Tumors in KLF6+/- Mice Recapitulate Aggressive Human Hepatocellular Carcinoma Associated with p53 Pathway Deregulation.  Hepatology. 54:(2)522-531.  Abstract
232.
Shema E., Oren M. & Minsky N. (2011). Detection and characterization of ubiquitylated H2B in mammalian cells.  Methods. 54:(3)326-330.  Abstract
231.
Zwang Y., Sas-Chen A., Drier Y., Shay T., Avraham R., Lauriola M., Shema E., Lidor Nili N. E., Jacob-Hirsch J., Amariglio N., Lu Y., Mills G. B., Rechavi G., Oren M., Domany E. & Yarden Y. (2011). Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals.  Molecular Cell. 42:(4)524-535.  Abstract
230.
Dell'Orso S., Fontemaggi G., Stambolsky P., Goeman F., Voellenkle C., Levrero M., Strano S., Rotter V., Oren M. & Blandino G. (2011). ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters.  Omics-A Journal Of Integrative Biology. 15:(5)305-312.  Abstract
229.
Shema E., Kim J., Roeder R. G. & Oren M. (2011). RNF20 Inhibits TFIIS-Facilitated Transcriptional Elongation to Suppress Pro-oncogenic Gene Expression.  Molecular Cell. 42:(4)477-488.  Abstract
228.
Gutekunst M., Oren M., Weilbacher A., Dengler M. A., Markwardt C., Thomale J., Aulitzky W. E. & van der Kuip d. K. H. (2011). p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin.  PLoS One. 6:(4)  Abstract
227.
Aylon Y. & Oren M. (2011). New plays in the p53 theater.  Current opinion in genetics & development. 21:(1)86-92.  Abstract
226.
Elyada E., Pribluda A., Goldstein R. E., Morgenstern Y., Brachya G., Cojocaru G., Snir-Alkalay I., Burstain I., Haffner-Krausz R., Jung S., Wiener Z., Alitalo K., Oren M., Pikarsky E. & Ben-Neriah Y. (2011). CKI alpha ablation highlights a critical role for p53 in invasiveness control.  Nature. 470:(7334)409-U208.  Abstract
225.
Goldstein I., Marcel V., Olivier M., Oren M., Rotter V. & Hainaut P. (2011). Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.  Cancer Gene Therapy. 18:(1)2-11.  Abstract
224.
Okada N., Yabuta N., Suzuki H., Aylon Y., Oren M. & Nojima H. (2011). A novel Chk1/2-Lats2-14-3-3 signaling pathway regulates P-body formation in response to UV damage.  Journal of Cell Science. 124:(1)57-67.  Abstract

2010

223.
Addadi Y., Moskovits N., Granot D., Lozano G., Carmi Y., Apte R. N., Neeman M. & Oren M. (2010). p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner.  Cancer Research. 70:(23)9650-9658.  Abstract
222.
Aylon Y., Ofir-Rosenfeld Y., Yabuta N., Lapi E., Nojima H., Lu X. & Oren M. (2010). The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1.  GENES & DEVELOPMENT. 24:(21)2420-2429.  Abstract
221.
Nili E. L., Field Y., Lubling Y., Widom J., Oren M. & Segal E. (2010). p53 binds preferentially to genomic regions with high DNA-encoded nucleosome occupancy.  Genome Research. 20:(10)1361-1368.  Abstract
220.
Scherz-Shouval R., Weidberg H., Gonen C., Wilder S., Elazar Z. & Oren M. (2010). p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation.  Proceedings of the National Academy of Sciences of the United States of America. 107:(43)18511-18516.  Abstract
219.
Shalgi R., Pilpel Y. & Oren M. (2010). Repression of transposable-elements - a microRNA anti-cancer defense mechanism?.  Trends in Genetics. 26:(6)253-259.  Abstract
218.
Schilling T., Kairat A., Melino G., Krammer P. H., Stremmel W., Oren M. & Mueller M. (2010). Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.  Biochemical and Biophysical Research Communications. 394:(3)817-823.  Abstract
217.
Oren M. & Cooks T. (2010). NF kappa B and p53: A life and death affair.  Cell Cycle. 9:(6)1027-1027.
216.
Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Sigfried Z., Shiff I., Kogan I., Shay M., Kalo E., Blandino G., Simon I., Oren M. & Rotter V. (2010). Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53.  Cancer Cell. 17:(3)273-285.  Abstract
215.
Bar J., Moskovits N. & Oren M. (2010). Involvement of stromal p53 in tumor-stroma interactions.  SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY. 21:(1)47-54.  Abstract
214.
Christoffersen N. R., Shalgi R., Frankel L. B., Leucci E., Lees M., Klausen M., Pilpel Y., Nielsen F. C., Oren M. & Lund A. H. (2010). p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.  Cell Death and Differentiation. 17:(2)236-245.  Abstract
213.
Oren M. & Rotter V. (2010). Mutant p53 Gain-of-Function in Cancer.  Cold Spring Harbor perspectives in biology. 2:(2)  Abstract

2009

212.
Aylon Y., Yabuta N., Besserglick H., Buganim Y., Rotter V., Nojima H. & Oren M. (2009). Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.  Oncogene. 28:(50)4469-4479.  Abstract
211.
Skorta I., Oren M., Markwardt C., Gutekunst M., Aulitzky W. E. & van der Kuip d. K. H. (2009). Imatinib Mesylate Induces Cisplatin Hypersensitivity in Bcr-Abl(+) Cells by Differential Modulation of p53 Transcriptional and Proapoptotic Activity.  Cancer Research. 69:(24)9337-9345.  Abstract
210.
Lavelin I., Beer A., Kam Z., Boner V., Oren M., Navon A. & Geiger B. (2009). Discovery of Novel Proteasome Inhibitors Using a High-Content Cell-Based Screening System.  PLoS One. 4:(12)  Abstract
209.
Levine A. J. & Oren M. (2009). The first 30 years of p53: growing ever more complex.  Nature Reviews Cancer. 9:(10)749-758.  Abstract
208.
Schilling T., Schleithoff E. S., Kairat A., Melino G., Stremmel W., Oren M., Krammer P. H. & Mueller M. (2009). Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family.  Biochemical and Biophysical Research Communications. 387:(2)399-404.  Abstract
207.
Shalgi R., Brosh R., Oren M., Pilpel Y. & Rotter V. (2009). Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate.  AGING-US. 1:(9)762-770.  Abstract
206.
Pirngruber J., Shchebet A., Schreiber L., Shema E., Minsky N., Chapman R. D., Eick D., Aylon Y., Oren M. & Johnsen S. A. (2009). CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3 '-end processing.  EMBO Reports. 10:(8)894-900.  Abstract
205.
Bar J., Feniger-Barish R., Lukashchuk N., Shaham H., Moskovits N., Goldfinger N., Simansky D., Perlman M., Papa M., Yosepovich A., Rechavi G., Rotter V. & Oren M. (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Oncogene. 28:(6)933-936.  Abstract

2008

204.
Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G. H., Enerly E., Johnsen H., Buganim Y., Solomon H., Goldstein I., Madar S., Goldfinger N., Brresen-Dale A., Ginsberg D., Harris C. C., Pilpel Y., Oren M. & Rotter V. (2008). p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.  Molecular Systems Biology. 4.  Abstract
203.
Shema E., Tirosh I., Aylon Y., Huang J., Ye C., Moskovits N., Raver-Shapira N., Minsky N., Pirngruber J., Tarcic G., Hublarova P., Moyal L., Gana-Weisz M., Shiloh Y., Yarden Y., Johnsen S. A., Vojtesek B., Berger S. L. & Oren M. (2008). The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression.  GENES & DEVELOPMENT. 22:(19)2664-2676.  Abstract
202.
Ofir-Rosenfeld Y., Boggs K., Michael D., Kastan M. B. & Oren M. (2008). Mdm2 Regulates p53 mRNA Translation through Inhibitory Interactions with Ribosomal Protein L26.  Molecular Cell. 32:(2)180-189.  Abstract
201.
Finkin S., Aylon Y., Anzi S., Oren M. & Shaulian E. (2008). Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy.  Oncogene. 27:(32)4411-4421.  Abstract
200.
Bossi G., Marampon F., Maor-Aloni R., Zani B., Rotter V., Oren M., Strano S., Blandino G. & Sacchi A. (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.  Cell Cycle. 7:(12)1870-1879.  Abstract
199.
Minsky N., Shema E., Field Y., Schuster M., Segal E. & Oren M. (2008). Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells.  Nature Cell Biology. 10:(4)483-490.  Abstract
198.
Abe Y., Oda-Sato E., Tobiume K., Kawauchi K., Taya Y., Okamoto K., Oren M. & Tanaka N. (2008). Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2.  Proceedings of the National Academy of Sciences of the United States of America. 105:(12)4838-4843.  Abstract

2007

197.
Lantner F., Starlets D., Gore Y., Flaishon L., Yamit-Hezi A., Dikstein R., Leng L., Bucala R., Machluf Y., Oren M. & Shachar I. (2007). CD74 induces TAp63 expression leading to B-cell survival.  Blood. 110:(13)4303-4311.  Abstract
196.
Raver-Shapira N. & Oren M. (2007). Tiny actors, great roles - MicroRNAs in p53's service.  Cell Cycle. 6:(21)2656-2661.  Abstract
195.
Lu X., Ma O., Nguyen T., Joness S. N., Oren M. & Donehower L. A. (2007). The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.  Cancer Cell. 12:(4)342-354.  Abstract
194.
Reef S., Shifman O., Oren M. & Kimchi A. (2007). The autophagic inducer smARF interacts with and is stabilized bythe mitochondrial p32 protein.  Oncogene. 26:(46)6677-6683.  Abstract
193.
Aylon Y. & Oren M. (2007). Living with p53, dying of p53.  Cell. 130:(4)597-600.  Abstract
192.
Shalgi R., Lieber D., Oren M. & Pilpel Y. (2007). Global and local architecture of the mammalian microRNA-transcription factor regulatory network.  PLoS Computational Biology. 3:(7)1291-1304.  Abstract
191.
Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z. & Oren M. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.  Molecular Cell. 26:(5)731-743.  Abstract
190.
Weisz L., Oren M. & Rotter V. (2007). Transcription regulation by mutant p53.  Oncogene. 26:(15)2202-2211.  Abstract
189.
Oren M. & Bartek J. (2007). The sunny side of p53.  Cell. 128:(5)826-828.  Abstract
188.
Shmueli A. & Oren M. (2007). Mdm2: p53's lifesaver?.  Molecular Cell. 25:(6)794-796.
187.
Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V. G., Rotter V., Blandino G. & Oren M. (2007). Mutant p53 enhances nuclear factor kappa B activation by tumor necrosis factor alpha in cancer cells.  Cancer Research. 67:(6)2396-2401.  Abstract

2006

186.
Stambolsky P., Weisz L., Shats I., Klein Y. A., Goldfinger N., Oren M. & Rotter V. (2006). Regulation of AIF expression by p53.  Cell Death and Differentiation. 13:(12)2140-2149.  Abstract
185.
Moskovits N., Kalinkovich A., Bar J. & Oren M. (2006). p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts.  Cancer Research. 66:(22)10671-10676.  Abstract
184.
Oren M. (2006). Tumor suppression by p53: Inside and outside the cancer cell.  Ejc Supplements. 4:(12)76-76.  Abstract
183.
Aylon Y., Michael D., Shmueli A., Yabuta N., Nojima H. & Oren M. (2006). A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization.  GENES & DEVELOPMENT. 20:(19)2687-2700.  Abstract
182.
Rentsch C. A., Germann M., Wetterwald A., Schwaninger R., Voller M., Rotter V., Oren M., Schalken J. A., Studer U. E., Thalmann G. N. & Cecchini M. G. (2006). Transforming growth factor stimulated clone 22 (TSC-22): Potential tumor suppressive role in prostate cancer and novel prostate basal cell marker.  European Urology Supplements. 5:(14)790-790.  Abstract
181.
Reef S., Zalckvar E., Shifman O., Bialik S., Sabanay H., Oren M. & Kimchi A. (2006). A short mitochondrial form of p19(ARF) induces autophagy and caspase-independent cell death.  Molecular Cell. 22:(4)463-475.  Abstract
180.
Avkin S., Sevilya Z., Toube L., Geacintov N., Chaney S., Oren M. & Livneh Z. (2006). p53 and p21 regulate error-prone DNA repair to yield a lower mutation load.  Molecular Cell. 22:(3)407-413.  Abstract
179.
Kogan I., Goldfinger N., Milyavsky M., Cohen M., Shats I., Dobler G., Klocker H., Wasylyk B., Voller M., Aalders T., Schalken J., Oren M. & Rotter V. (2006). hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.  Cancer Research. 66:(7)3531-3540.  Abstract
178.
Margalit O., Amram H., Amariglio N., Simon A., Shaklai S., Granot G., Minsky N., Shimoni A., Harmelin A., Givol D., Shohat M., Oren M. & Rechavi G. (2006). BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.  Blood. 107:(4)1599-1607.  Abstract
177.
OREN M., DAMALAS A., GOTTLIEB T., MICHAEL D., TAPLICK J., LEAL J. F. M., MAYA R., MOAS M., SEGER R., TAYA Y. & BEN-ZE'EV A. (2006). Regulation of p53: intricate loops and delicate balances.  Annals of the New York Academy of Sciences. 973:(1)374-383.  Abstract
176.
Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V. & Oren M. (2006). Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.  Oncogene. 25:(3)359-369.  Abstract

2005

175.
Muller M., Schilling T., Sayan A., Kairat A., Lorenz K., Schulze-Bergkamen H., Oren M., Koch A., Tannapfel A., Stremmel W., Melino G. & Krammer P. (2005). TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.  Cell Death and Differentiation. 12:(12)1564-1577.  Abstract
174.
Bar J., Lukaschuk N., Zalcenstein A., Wilder S., Seger R. & Oren M. (2005). The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis.  Cell Death and Differentiation. 12:(12)1578-1587.  Abstract
173.
Shmueli A. & Oren M. (2005). Life, death, and ubiquitin: Taming the mule.  Cell. 121:(7)963-965.  Abstract
172.
Gressner O., Schilling T., Lorenz K., Schleithoff E., Koch A., Schulze-Bergkamen H., Lena A., Candi E., Terrinoni A., Catani M., Oren M., Melino G., Krammer P., Stremmel W. & Muller M. (2005). TAp63 alpha induces apoptosis by activating signaling via death receptors and mitochondria.  EMBO Journal. 24:(13)2458-2471.  Abstract
171.
Oberst A., Rossi M., Salornoni P., Pandolfi P., Oren M., Melino G. & Bernassola F. (2005). Regulation of the p73 protein stability and degradation.  Biochemical and Biophysical Research Communications. 331:(3)707-712.  Abstract
170.
Hershko T., Chaussepied M., Oren M. & Ginsberg D. (2005). Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F.  Cell Death and Differentiation. 12:(4)377-383.  Abstract
169.
Wohlbold L., van der Kuip d. K. H., Moehring A., Granot G., Oren M., Vornlocher H. & Aulitzky W. (2005). All common p210 and p190 Bcr-abl variants can be targeted by RNA interference.  Leukemia. 19:(2)290-292.
168.
Damalas A., Weis L., Nordgard S., Kristensen V., Gardner K., Cheng G., Gelinas C., Levrero M., Strano S., Borresen-Dale A., Rotter V., Oren M. & Blandino G. (2005). Mutant p53 exerts its gain of function through activation of the NF-kappa B pathway.  Breast Cancer Research. 7:S53-S53.  Abstract

2004

167.
Minsky N. & Oren M. (2004). The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.  Molecular Cell. 16:(4)631-639.  Abstract
166.
Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M. & Rotter V. (2004). Transactivation of the EGR1 gene contributes to mutant p53 gain of function.  Cancer Research. 64:(22)8318-8327.  Abstract
165.
Oren M., Iron M., Burcat A. & Martin J. (2004). Thermodynamic properties of C-1 and C-2 bromo compounds and radicals. A relativistic ab initio study.  Journal of Physical Chemistry A. 108:(38)7752-7761.  Abstract
164.
Daniely Y., Liao G., Dixon D., Linnoila R., Lori A., Randell S., Oren M. & Jetten A. (2004). Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium.  American Journal Of Physiology-Cell Physiology. 287:(1)C171-C181.  Abstract
163.
Levina E., Oren M. & Ben-Ze'ev A. (2004). Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics.  Oncogene. 23:(25)4444-4453.  Abstract
162.
Bar J., Cohen-Noyman E., Geiger B. & Oren M. (2004). Attenuation of the p53 response to DNA damage by high cell density.  Oncogene. 23:(12)2128-2137.  Abstract
161.
Fiucci G., Beaucourt S., Duflaut D., Lespagnol A., Stumptner-Cuvelette P., Geant A., Buchwalter G., Tuynder M., Susini L., Lassalle J., Wasylyk C., Wasylyk B., Oren M., Amson R. & Telerman A. (2004). Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter.  Proceedings of the National Academy of Sciences of the United States of America. 101:(10)3510-3515.  Abstract
160.
Wang X., Taplick J., Geva N. & Oren M. (2004). Inhibition of p53 degradation by Mdm2 acetylation.  FEBS Letters. 561:(3-Jan)195-201.  Abstract
159.
Shmueli A. & Oren M. (2004). Regulation of p53 by Mdm2: Fate is in the numbers.  Molecular Cell. 13:(1)4-5.

2003

158.
Zalcenstein A., Stambolsky P., Weisz L., Muller M., Wallach D., Goncharov T., Krammer P., Rotter V. & Oren M. (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.  Oncogene. 22:(36)5667-5676.  Abstract
157.
Ofek P., Ben-Meir D., Kariv-Inbal Z., Oren M. & Lavi S. (2003). Cell cycle regulation and p53 activation by protein phosphatase 2C alpha.  Journal of Biological Chemistry. 278:(16)14299-14305.  Abstract
156.
Wang X., Zalcenstein A. & Oren M. (2003). Nitric oxide promotes p53 nuclear retention and sensitizes neuroblastoma cells to apoptosis by ionizing radiation.  Cell Death and Differentiation. 10:(4)468-476.  Abstract
155.
Oren M. (2003). Decision making by p53: life, death and cancer.  Cell Death and Differentiation. 10:(4)431-442.  Abstract
154.
Passer B., Nancy-Portebois V., Amzallag N., Prieur S., Cans C., de Climens C. A., Fiucci G., Bouvard V., Tuynder M., Susini L., Morchoisne S., Crible V., Lespagnol A., Dausset J., Oren M., Amson R. & Telerman A. (2003). The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase.  Proceedings of the National Academy of Sciences of the United States of America. 100:(5)2284-2289.  Abstract
153.
Michael D. Y. & Oren M. (2003). The p53-Mdm2 module and the ubiquitin system.  Seminars in Cancer Biology. 13:(1)49-58.  Abstract
152.
Lavon I., Pikarsky E., Gutkovich E., Goldberg I., Bar J., Oren M. & Ben-Neriah Y. (2003). Nuclear factor-kappa B protects the liver against genotoxic stress and functions independently of p53.  Cancer Research. 63:(1)25-30.  Abstract

2002

151.
Blander G., Zalle N., Daniely Y., Taplick J., Gray M. & Oren M. (2002). DNA damage-induced translocation of the Werner helicase is regulated by acetylation.  Journal of Biological Chemistry. 277:(52)50934-50940.  Abstract
150.
Balass M., Kalef E., Maya R., Wilder S., Oren M. & Katchalski-Katzir E. (2002). Characterization of two peptide epitopes on Mdm2 oncoprotein that affect p53 degradation.  Peptides. 23:(10)1719-1725.  Abstract
149.
Shtutman M., Zhurinsky J., Oren M., Levina E. & Ben-Ze'ev A. (2002). PML is a target gene of β-catenin and plakoglobin, and coactivates β-catenin-mediated transcription.  Cancer Research. 62:(20)5947-5954.  Abstract
148.
Courtois S., Verhaegh G., North S., Luciani M., Lassus P., Hibner U., Oren M. & Hainaut P. (2002). Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53.  Oncogene. 21:(44)6722-6728.  Abstract
147.
Goldberg Z., Vogt Sionov S. R., Berger M., Zwang Y., Perets R., Van Etten E. R., Oren M., Taya Y. & Haupt Y. (2002). Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation.  EMBO Journal. 21:(14)3715-3727.  Abstract
146.
Wang X., Michael D. Y., de Murcia M. G. & Oren M. (2002). p53 activation by nitric oxide involves down-regulation of Mdm2.  Journal of Biological Chemistry. 277:(18)15697-15702.  Abstract
145.
Strano S., Fontemaggi G., Costanzo A., Rizzo M., Monti O., Baccarini A., Del Sal S. G., Levrero M., Sacchi A., Oren M. & Blandino G. (2002). Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.  Journal of Biological Chemistry. 277:(21)18817-18826.  Abstract
144.
Folberg-Blum A., Sapir A., Shilo B. & Oren M. (2002). Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila.  Oncogene. 21:(15)2413-2417.  Abstract
143.
Michael D. Y. & Oren M. (2002). The p53 and Mdm2 families in cancer.  Current opinion in genetics & development. 12:(1)53-59.  Abstract
142.
Gottlieb T., Leal J., Seger R., Taya Y. & Oren M. (2002). Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis.  Oncogene. 21:(8)1299-1303.  Abstract

2001

141.
Susini L., Passer B., Amzallag-Elbaz N., Juven-Gershon T., Prieur S., Privat N., Tuynder M., Gendron M., Israel A., Amson R., Oren M. & Telerman A. (2001). Siah-1 binds and regulates the function of Numb.  Proceedings of the National Academy of Sciences of the United States of America. 98:(26)15067-15072.  Abstract
140.
Sadot E., Geiger B., Oren M. & Ben-Ze'ev A. (2001). Down-regulation of beta-catenin by activated p53.  Molecular and Cellular Biology. 21:(20)6768-6781.  Abstract
139.
Goetz A., van der Kuip d. K. H., Maya R., Oren M. & Aulitzky W. (2001). Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.  Cancer Research. 61:(20)7635-7641.  Abstract
138.
Damalas A., Kahan S., Shtutman M., Ben-Ze'ev A. & Oren M. (2001). Deregulated beta-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation.  EMBO Journal. 20:(17)4912-4922.  Abstract
137.
Maya R., Balass M., Kim S., Shkedy D., Leal J., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., Kastan M., Katzir E. & Oren M. (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.  GENES & DEVELOPMENT. 15:(9)1067-1077.  Abstract
136.
Strano S., Munarriz E., Rossi M., Castagnoli L., Shaul Y., Sacchi A., Oren M., Sudol M., Cesareni G. & Blandino G. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity.  Journal of Biological Chemistry. 276:(18)15164-15173.  Abstract

2000

135.
Blander G., Zalle N., Leal J., Bar-Or R., Yu C. & Oren M. (2000). The Warner syndrome protein contributes to induction of p53 by DNA damage.  FASEB Journal. 14:(14)2138-2140.
134.
Reinstein E., Scheffner M., Oren M., Ciechanover A. & Schwartz A. (2000). Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue.  Oncogene. 19:(51)5944-5950.  Abstract
133.
Bar-Or R., Maya R., Segel L., Alon U., Levine A. & Oren M. (2000). Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study.  Proceedings of the National Academy of Sciences of the United States of America. 97:(21)11250-11255.  Abstract
132.
Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M. & McCormick F. (2000). Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19(ARF).  Cell. 103:(2)321-330.  Abstract
131.
Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., Levine A., Sacchi A., Cesareni G., Oren M. & Blandino G. (2000). Physical and functional interaction between p53 mutants and different isoforms of p73.  Journal of Biological Chemistry. 275:(38)29503-29512.  Abstract
130.
Maya R. & Oren M. (2000). Unmasking of phosphorylation-sensitive epitopes on p53 and Mdm2 by a simple Western-phosphatase procedure.  Oncogene. 19:(28)3213-3215.  Abstract
129.
Amson R., Lassalle J., Halley H., Prieur S., Lethrosne F., Roperch J., Israeli D., Gendron M., Duyckaerts C., Checler F., Dausset J., Cohen D., Oren M. & Telerman A. (2000). Behavioral alterations associated with apoptosis and down-regulation of presenilin 1 in the brains of p53-deficient mice.  Proceedings of the National Academy of Sciences of the United States of America. 97:(10)5346-5350.  Abstract
128.
de Rozieres R. S., Maya R., Oren M. & Lozano G. (2000). The loss of mdm2 induces p53 mediated apoptosis.  Oncogene. 19:(13)1691-1697.  Abstract

1999

127.
Khosravi R., Maya R., Gottlieb T., Oren M., Shiloh Y. & Shkedy D. (1999). Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.  Proceedings of the National Academy of Sciences of the United States of America. 96:(26)14973-14977.  Abstract
126.
Oren M. (1999). Regulation of the p53 tumor suppressor protein.  Journal of Biological Chemistry. 274:(51)36031-36034.
125.
Blander G., Kipnis J., Leal J., Yu C., Schellenberg G. & Oren M. (1999). Physical and functional interaction between p53 and the Werner's syndrome protein.  Journal of Biological Chemistry. 274:(41)29463-29469.  Abstract
124.
Roperch J., Lethrone F., Prieur S., Piouffre L., Israeli D., Tuynder M., Nemani M., Pasturaud P., Gendron M., Dausset J., Oren M., Amson R. & Telerman A. (1999). SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: Identification of common effectors with p53 and p21(Waf1).  Proceedings of the National Academy of Sciences of the United States of America. 96:(14)8070-8073.  Abstract
123.
Agami R., Blandino G., Oren M. & Shaul Y. (1999). Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis.  Nature. 399:(6738)809-813.  Abstract
122.
Oren M. & Vousden K. (1999). Hot papers - Cancer research - Mdm2 promotes the rapid degradation of p53 by Y. Haupt, R. Maya, A. Kazaz, M. Oren and Regulation of p53 stability by Mdm2 by M.H.G. Kubbutat, S.N. Jones, K.H. Vousden - Comments.  Scientist. 13:(12)11-11.  Abstract
121.
Damalas A., Ben-Ze'ev A., Simcha I., Shtutman N., Leal J., Zhurinsky J., Geiger B. & Oren M. (1999). Excess beta-catenin promotes accumulation of transcriptionally active p53.  EMBO Journal. 18:(11)3054-3063.  Abstract
120.
Unger T., Sionov R., Moallem E., Yee C., Howley P., Oren M. & Haupt Y. (1999). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.  Oncogene. 18:(21)3205-3212.  Abstract
119.
Zeng X., Chen L., Jost C., Maya R., Keller D. A., Wang X., Kaelin W., Oren M., Chen J. & Lu H. (1999). MDM2 suppresses p73 function without promoting p73 degradation.  Molecular and Cellular Biology. 19:(5)3257-3266.  Abstract
118.
Unger T., Juven-Gershon T., Moallem E., Berger M., Sionov R., Lozano G., Oren M. & Haupt Y. (1999). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.  EMBO Journal. 18:(7)1805-1814.  Abstract
117.
Elkeles A., Juven-Gershon T., Israeli D., Wilder S., Zalcenstein A. & Oren M. (1999). The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor.  Molecular and Cellular Biology. 19:(4)2594-2600.  Abstract
116.
Sionov R., Moallem E., Berger M., Kazaz A., Gerlitz O., Ben-Neriah Y., Oren M. & Haupt Y. (1999). c-Abl neutralizes the inhibitory effect of Mdm2 on p53.  Journal of Biological Chemistry. 274:(13)8371-8374.  Abstract
115.
Juven-Gershon T. & Oren M. (1999). Mdm2: The ups and downs.  Molecular Medicine. 5:(2)71-83.
114.
Blandino G., Levine A. & Oren M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.  Oncogene. 18:(2)477-485.  Abstract
113.
Oren M. & Rotter V. (1999). Introduction: p53 - the first twenty years.  Cellular and Molecular Life Sciences. 55:(1)9-11.  Abstract

1998

112.
Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S., Galle P., Stremmel W., Oren M. & Krammer P. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.  Journal of Experimental Medicine. 188:(11)2033-2045.  Abstract
111.
Hosokawa K., Aharoni D., Dantes A., Shaulian E., Schere-Levy C., Atzmon R., Kotsuji F., Oren M., Vlodavsky I. & Amsterdam A. (1998). Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells.  Endocrinology. 139:(11)4688-4700.  Abstract
110.
Gottlieb T. & Oren M. (1998). p53 and apoptosis.  Seminars in Cancer Biology. 8:(5)359-368.  Abstract
109.
Wang Y., Blandino G., Oren M. & Givol D. (1998). Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs.  Oncogene. 17:(15)1923-1930.  Abstract
108.
Yardley G., Zauberman A., Oren M. & Jackson P. (1998). Individual promoter and intron p53-binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53 but do not show co-operative activation.  FEBS Letters. 430:(3)171-175.  Abstract
107.
Juven-Gershon T., Shifman O., Unger T., Elkeles A., Haupt Y. & Oren M. (1998). The Mdm2 oncoprotein interacts with the cell fate regulator numb.  Molecular and Cellular Biology. 18:(7)3974-3982.  Abstract
106.
Gottlieb E. & Oren M. (1998). p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53.  EMBO Journal. 17:(13)3587-3596.  Abstract
105.
Roperch J., Alvaro V., Prieur S., Tuynder M., Nemani M., Lethrosne F., Piouffre L., Gendron M., Israeli D., Dausset J., Oren M., Amson R. & Telerman A. (1998). Inhibition of presenilin 1 expression is promoted by p53 and p21(WAF-1) and results in apoptosis and tumor suppression.  Nature Medicine. 4:(7)835-838.  Abstract
104.
Oren M. (1998). Tumour suppressors - Teaming up to restrain cancer.  Nature. 391:(6664)233-234.
103.
Ori A., Zauberman A., Doitsh G., Paran N., Oren M. & Shaul Y. (1998). p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.  EMBO Journal. 17:(2)544-553.  Abstract

1997

102.
Shaulian E., Resnitzky D., Shifman O., Blandino G., Amsterdam A., Yayon A. & Oren M. (1997). Induction of Mdm2 and enhancement of cell survival by bFGF.  Oncogene. 15:(22)2717-2725.  Abstract
101.
Zauberman A., Oren M. & Zipori D. (1997). Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition.  Oncogene. 15:(14)1705-1711.  Abstract
100.
Oren M. (1997). Lonely no more: p53 finds its kin in a tumor suppressor haven.  Cell. 90:(5)829-832.
99.
Israeli D., Tessler E., Haupt Y., Elkeles A., Wilder S., Amson R., Telerman A. & Oren M. (1997). A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis.  EMBO Journal. 16:(14)4384-4392.  Abstract
98.
Friedman S., Shaulian E., Littlewood T., Resnitzky D. & Oren M. (1997). Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells.  Oncogene. 15:(1)63-70.  Abstract
97.
Haupt Y., Maya R., Kazaz A. & Oren M. (1997). Mdm2 promotes the rapid degradation of p53.  Nature. 387:(6630)296-299.  Abstract
96.
Ruaro E., Collavin L., DelSal G., Haffner R., Oren M., Levine A. & Schneider C. (1997). A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1.  Proceedings of the National Academy of Sciences of the United States of America. 94:(9)4675-4680.  Abstract
95.
Gottlieb E., Haffner R., King A., Asher G., Gruss P., Lonai P. & Oren M. (1997). Transgenic mouse model for studying the transcriptional activity of the p53 protein: Age- and tissue-dependent changes in radiation-induced activation during embryogenesis.  EMBO Journal. 16:(6)1381-1390.  Abstract
94.
Hansen R. & Oren M. (1997). p53; From inductive signal to cellular effect.  Current opinion in genetics & development. 7:(1)46-51.  Abstract

1996

93.
Oren M. & Prives C. (1996). p53: Upstream, downstream and off stream - Review of the 8th p53 workshop (Dundee, July 5-9, 1996).  Biochimica Et Biophysica Acta-Reviews On Cancer. 1288:(3)R13-R19.
92.
Friedlander P., Haupt Y., Prives C. & Oren M. (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.  Molecular and Cellular Biology. 16:(9)4961-4971.  Abstract
91.
Eizenberg O., FaberElman A., Gottlieb E., Oren M., Rotter V. & Schwartz M. (1996). p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells.  Molecular and Cellular Biology. 16:(9)5178-5185.  Abstract
90.
Tanaka N., Ishihara M., Lamphier M., Nozawa H., Matsuyama T., Mak T., Aizawa S., Tokino T., Oren M. & Taniguchi T. (1996). Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage.  Nature. 382:(6594)816-818.  Abstract
89.
Nemani M., LinaresCruz G., BruzzoniGiovanelli H., Roperch J., Tuynder M., Bougueleret L., Cherif D., Medhioub M., Pasturaud P., Alvaro V., DerSarkissan H., Cazes L., LePaslier D., LeGall I., Israeli D., Dausset J., Sigaux F., Chumakov I. & Oren M. (1996). Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression.  Proceedings of the National Academy of Sciences of the United States of America. 93:(17)9039-9042.  Abstract
88.
Bacus S., Yarden Y., Oren M., Chin D., Lyass L., Zelnick C., Kazarov A., Toyofuku W., GrayBablin J., Beerli R., Hynes N., Nikiforov M., Haffner R., Gudkov A. & Keyomarsi K. (1996). Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.  Oncogene. 12:(12)2535-2547.  Abstract
87.
Gottlieb T. & Oren M. (1996). p53 in growth control and neoplasia.  Biochimica Et Biophysica Acta-Reviews On Cancer. 1287:(3-Feb)77-102.
86.
Bowman T., Symonds H., Gu L., Yin C., Oren M. & VanDyke T. (1996). Tissue-specific inactivation of p53 tumor suppression in the mouse.  GENES & DEVELOPMENT. 10:(7)826-835.  Abstract
85.
Haupt Y., Barak Y. & Oren M. (1996). Cell type-specific inhibition of p53-mediated apoptosis by mdm2.  EMBO Journal. 15:(7)1596-1606.  Abstract
84.
Knippschild U., Oren M. & Deppert W. (1996). Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion.  Oncogene. 12:(8)1755-1765.  Abstract
83.
Gottlieb E., Lindner S. & Oren M. (1996). Relationship of sequence-specific transactivation and p53-regulated apoptosis in interleukin 3-dependent hematopoietic cells.  Cell Growth & Differentiation. 7:(3)301-310.  Abstract
82.
Rowan S., Ludwig R., Haupt Y., Bates S., Lu X., Oren M. & Vousden K. (1996). Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.  EMBO Journal. 15:(4)827-838.  Abstract
81.
Haupt Y., Rowan S., Shaulian E., Gottlieb E., YonishRouach E., Vousden K. & Oren M. (1996). p53-Mediated apoptosis - Regulatory and mechanistic aspects.  Cancer Genes: Functional Aspects. 7:83-101.  Abstract

1995

80.
HIEBERT S., PACKHAM G., STROM D., HAFFNER R., Oren M., ZAMBETTI G. & CLEVELAND J. (1995). E2F-1/DP-1 INDUCES P53 AND OVERRIDES SURVIVAL FACTORS TO TRIGGER APOPTOSIS.  Molecular and Cellular Biology. 15:(12)6864-6874.  Abstract
79.
Harlow E., Tlsty T., Courtneidge S., McCormick F., Tocque B., Yaniv M., Woude G., Herlich P., Bohmann D., Howley P., Levine A., Prives C., Lane D., Oren M., Kimchi A., Thomas G. & Feuteun J. (1995). Cancer: The translation of advances in basic science to human therapy. 22-27 July, 1995 - La fondation des Treilles, Tourtour, France - Discussion.  Comptes Rendus De L Academie Des Sciences Serie Iii-Sciences De La Vie-Life Sciences. 318:(11)1173-1179.
78.
STUART E., HAFFNER R., Oren M. & GRUSS P. (1995). LOSS OF P53 FUNCTION THROUGH PAX-MEDIATED TRANSCRIPTIONAL REPRESSION.  EMBO Journal. 14:(22)5638-5645.  Abstract
77.
MALCOMSON R., Oren M., WYLLIE A. & HARRISON D. (1995). P53-INDEPENDENT DEATH AND P53-INDUCED PROTECTION AGAINST APOPTOSIS IN FIBROBLASTS TREATED WITH CHEMOTHERAPEUTIC DRUGS.  British Journal of Cancer. 72:(4)952-957.  Abstract
76.
HAUPT Y., ROWAN S., SHAULIAN E., VOUSDEN K. & Oren M. (1995). INDUCTION OF APOPTOSIS IN HELA-CELLS BY TRANS-ACTIVATION-DEFICIENT P53.  GENES & DEVELOPMENT. 9:(17)2170-2183.  Abstract
75.
Zauberman A., FLUSBERG D., HAUPT Y., Barak Y. & Oren M. (1995). A FUNCTIONAL P53-RESPONSIVE INTRONIC PROMOTER IS CONTAINED WITHIN THE HUMAN MDM2 GENE.  Nucleic Acids Research. 23:(14)2584-2592.  Abstract
74.
Zauberman A., LUPO A. & Oren M. (1995). IDENTIFICATION OF P53 TARGET GENES THROUGH IMMUNE SELECTION OF GENOMIC DNA - THE CYCLIN-G GENE CONTAINS 2 DISTINCT P53 BINDING-SITES.  Oncogene. 10:(12)2361-2366.  Abstract
73.
AHARONI D., Dantes A., Oren M. & Amsterdam A. (1995). CAMP-MEDIATED SIGNALS AS DETERMINANTS FOR APOPTOSIS IN PRIMARY GRANULOSA-CELLS.  Experimental Cell Research. 218:(1)271-282.  Abstract
72.
KERENTAL I., SUH B., Dantes A., LINDNER S., Oren M. & Amsterdam A. (1995). INVOLVEMENT OF P53 EXPRESSION IN CAMP-MEDIATED APOPTOSIS IN IMMORTALIZED GRANULOSA-CELLS.  Experimental Cell Research. 218:(1)283-295.  Abstract
71.
HAUPT Y., ROWAN S. & Oren M. (1995). P53-MEDIATED APOPTOSIS IN HELA-CELLS CAN BE OVERCOME BY EXCESS PRB.  Oncogene. 10:(8)1563-1571.  Abstract
70.
EIZENBERG O., FABERELMAN A., GOTTLIEB E., Oren M., Rotter V. & Schwartz M. (1995). DIRECT INVOLVEMENT OF P53 IN PROGRAMMED CELL-DEATH OF OLIGODENDROCYTES.  EMBO Journal. 14:(6)1136-1144.  Abstract
69.
CORVI R., SAVELYEVA L., BREIT S., WENZEL A., HANDGRETINGER R., BARAK J., Oren M., AMLER L. & SCHWAB M. (1995). NON-SYNTENIC AMPLIFICATION OF MDM2 AND MYCN IN HUMAN NEUROBLASTOMA.  Oncogene. 10:(6)1081-1086.  Abstract
68.
SHAULIAN E., HAVIV I., Shaul Y. & Oren M. (1995). TRANSCRIPTIONAL REPRESSION BY THE C-TERMINAL DOMAIN OF P53.  Oncogene. 10:(4)671-680.  Abstract

1994

67.
Barak Y., GOTTLIEB E., JUVENGERSHON T. & Oren M. (1994). REGULATION OF MDM2 EXPRESSION BY P53 - ALTERNATIVE PROMOTERS PRODUCE TRANSCRIPTS WITH NONIDENTICAL TRANSLATION POTENTIAL.  GENES & DEVELOPMENT. 8:(15)1739-1749.  Abstract
66.
Oren M. (1994). RELATIONSHIP OF P53 TO THE CONTROL OF APOPTOTIC CELL-DEATH.  Seminars in Cancer Biology. 5:(3)221-227.
65.
CIECHANOVER A., SHKEDY D., Oren M. & BERCOVICH B. (1994). DEGRADATION OF THE TUMOR-SUPPRESSOR PROTEIN-P53 BY THE UBIQUITIN-MEDIATED PROTEOLYTIC SYSTEM REQUIRES A NOVEL SPECIES OF UBIQUITIN-CARRIER PROTEIN, E2.  Journal of Biological Chemistry. 269:(13)9582-9589.  Abstract
64.
GOTTLIEB E., HAFFNER R., VONRUDEN T., WAGNER E. & Oren M. (1994). DOWN-REGULATION OF WILD-TYPE P53 ACTIVITY INTERFERES WITH APOPTOSIS OF IL-3-DEPENDENT HEMATOPOIETIC-CELLS FOLLOWING IL-3 WITHDRAWAL.  EMBO Journal. 13:(6)1368-1374.  Abstract
63.
Barak Y., LUPO A., Zauberman A., JUVEN T., ALONIGRINSTEIN R., GOTTLIEB E., Rotter V. & Oren M. (1994). TARGETS FOR TRANSCRIPTIONAL ACTIVATION BY WILD-TYPE P53 - ENDOGENOUS RETROVIRAL LTR, IMMUNOGLOBULIN-LIKE PROMOTER, AND AN INTERNAL PROMOTER OF THE MDM2 GENE.  Cold Spring Harbor Symposia on Quantitative Biology. 59:225-235.  Abstract
62.
GOTTLIEB E., HAFFNER R., YONISHROUACH E., VONRUDEN T., WAGNER E. & Oren M. (1994). WILD-TYPE P(53) ACTIVITY CONTRIBUTES TO DEPENDENCE ON HEMATOPOIETIC SURVIVAL FACTORS.  Apoptosis. 5:31-45.  Abstract

1993

61.
Levy N., YONISHROUACH E., Oren M. & Kimchi A. (1993). COMPLEMENTATION BY WILD-TYPE P53 OF INTERLEUKIN-6 EFFECTS ON M1 CELLS - INDUCTION OF CELL-CYCLE EXIT AND COOPERATIVITY WITH C-MYC SUPPRESSION.  Molecular and Cellular Biology. 13:(12)7942-7952.  Abstract
60.
JUVEN T., Barak Y., Zauberman A., GEORGE D. & Oren M. (1993). WILD-TYPE P53 CAN MEDIATE SEQUENCE-SPECIFIC TRANSACTIVATION OF AN INTERNAL PROMOTER WITHIN THE MDM2 GENE.  Oncogene. 8:(12)3411-3416.  Abstract
59.
Telerman A., TUYNDER M., DUPRESSOIR T., ROBAYE B., SIGAUX F., SHAULIAN E., Oren M., ROMMELAERE J. & AMSON R. (1993). A MODEL FOR TUMOR SUPPRESSION USING H-1 PARVOVIRUS.  Proceedings of the National Academy of Sciences of the United States of America. 90:(18)8702-8706.  Abstract
58.
Zauberman A., Barak Y., RAGIMOV N., Levy N. & Oren M. (1993). SEQUENCE-SPECIFIC DNA-BINDING BY P53 - IDENTIFICATION OF TARGET SITES AND LACK OF BINDING TO P53MDM2 COMPLEXES.  EMBO Journal. 12:(7)2799-2808.  Abstract
57.
SHAULIAN E., Zauberman A., MILNER J., DAVIES E. & Oren M. (1993). TIGHT DNA-BINDING AND OLIGOMERIZATION ARE DISPENSABLE FOR THE ABILITY OF P53 TO TRANSACTIVATE TARGET GENES AND SUPPRESS TRANSFORMATION.  EMBO Journal. 12:(7)2789-2797.  Abstract
56.
Oren M. (1993). ALONI, YOSEF - (1936-1993) - OBITUARY.  Oncogene. 8:(6)1405-1405.
55.
RAGIMOV N., KRAUSKOPF A., NAVOT N., Rotter V., Oren M. & ALONI Y. (1993). WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF.  Oncogene. 8:(5)1183-1193.  Abstract
54.
YONISHROUACH E., GRUNWALD D., Wilder S., Kimchi A., MAY E., LAWRENCE J., MAY P. & Oren M. (1993). P53-MEDIATED CELL-DEATH - RELATIONSHIP TO CELL-CYCLE CONTROL.  Molecular and Cellular Biology. 13:(3)1415-1423.  Abstract
53.
Barak Y., JUVEN T., HAFFNER R. & Oren M. (1993). MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY.  EMBO Journal. 12:(2)461-468.  Abstract

1992

52.
SHAULIAN E., Zauberman A., GINSBERG D. & Oren M. (1992). IDENTIFICATION OF A MINIMAL TRANSFORMING DOMAIN OF P53 - NEGATIVE DOMINANCE THROUGH ABROGATION OF SEQUENCE-SPECIFIC DNA-BINDING.  Molecular and Cellular Biology. 12:(12)5581-5592.  Abstract
51.
YEHIELY F. & Oren M. (1992). THE GENE FOR THE RAT HEAT-SHOCK COGNATE, HSC70, CAN SUPPRESS ONCOGENE-MEDIATED TRANSFORMATION.  Cell Growth & Differentiation. 3:(11)803-809.  Abstract
50.
Oren M. (1992). P53 - THE ULTIMATE TUMOR SUPPRESSOR GENE.  FASEB Journal. 6:(13)3169-3176.  Abstract
49.
Oren M. (1992). THE INVOLVEMENT OF ONCOGENES AND TUMOR SUPPRESSOR GENES IN THE CONTROL OF APOPTOSIS.  Cancer and Metastasis Reviews. 11:(2)141-148.
48.
Barak Y. & Oren M. (1992). ENHANCED BINDING OF A 95-KDA PROTEIN TO P53 IN CELLS UNDERGOING P53-MEDIATED GROWTH ARREST.  EMBO Journal. 11:(6)2115-2121.  Abstract

1991

47.
EIZENBERG O. & Oren M. (1991). REDUCED LEVELS OF ALPHA-1 (I) COLLAGEN MESSENGER-RNA IN CELLS IMMORTALIZED BY MUTANT P53 OR TRANSFORMED BY RAS.  Biochimica Et Biophysica Acta. 1129:(1)34-42.  Abstract
46.
GINSBERG D., MECHTA F., Yaniv M. & Oren M. (1991). WILD-TYPE P53 CAN DOWN-MODULATE THE ACTIVITY OF VARIOUS PROMOTERS.  Proceedings of the National Academy of Sciences of the United States of America. 88:(22)9979-9983.  Abstract
45.
Halevy O., RODEL J., Peled A. & Oren M. (1991). FREQUENT P53 MUTATIONS IN CHEMICALLY-INDUCED MURINE FIBROSARCOMA.  Oncogene. 6:(9)1593-1600.  Abstract
44.
Michael D., YEHIELY F., GOTTLIEB E. & Oren M. (1991). SIMIAN VIRUS-40 CAN OVERCOME THE ANTIPROLIFERATIVE EFFECT OF WILD-TYPE-P53 IN THE ABSENCE OF STABLE LARGE T-ANTIGEN-P53 BINDING.  Journal of Virology. 65:(8)4160-4168.  Abstract
43.
YONISHROUACH E., RESNITZKY D., Lotem J., Sachs L., Kimchi A. & Oren M. (1991). WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6.  Nature. 352:(6333)345-347.  Abstract
42.
GINSBERG D., HIRAI S., PINHASIKIMHI O., Yaniv M. & Oren M. (1991). TRANSFECTED MOUSE C-JUN CAN INHIBIT TRANSFORMATION OF PRIMARY RAT EMBRYO FIBROBLASTS.  Oncogene. 6:(4)669-672.  Abstract
41.
MICHALOVITZ D., Halevy O. & Oren M. (1991). P53 MUTATIONS - GAINS OR LOSSES.  Journal of Cellular Biochemistry. 45:(1)22-29.  Abstract
40.
GINSBERG D., Michael D. & Oren M. (1991). Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein.  Molecular and Cellular Biology. 11:(1)582-585.  Abstract

1990

39.
Halevy O., MICHALOVITZ D. & Oren M. (1990). Different tumor-derived p53 mutants exhibit distinct biological activities.  Science. 250:(4977)113-116.  Abstract
38.
GINSBERG D., Oren M., Yaniv M. & PIETTE J. (1990). PROTEIN-BINDING ELEMENTS IN THE PROMOTER REGION OF THE MOUSE P53 GENE.  Oncogene. 5:(9)1285-1290.
37.
MICHALOVITZ D., Halevy O. & Oren M. (1990). Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.  Cell. 62:(4)671-680.
36.
Eliyahu D., Michael D. Y., Eliyahu S., Pinchas-Kimhi O. & Oren M. (1990). p53 — Oncogene or Anti-Oncogene?.  Oncogenes in Cancer Diagnosis. 125-134.

1989

35.
Eliyahu D., MICHALOVITZ D., ELIYAHU S., PINHASIKIMHI O. & Oren M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation.  Proceedings of the National Academy of Sciences of the United States of America. 86:(22)8763-8767.
34.
Halevy O., HALL A. & Oren M. (1989). STABILIZATION OF THE P53 TRANSFORMATION-RELATED PROTEIN IN MOUSE FIBRO-SARCOMA CELL-LINES - EFFECTS OF PROTEIN-SEQUENCE AND INTRACELLULAR ENVIRONMENT.  Molecular and Cellular Biology. 9:(8)3385-3392.
33.
MICHALOVITZ D., Amsterdam A. & Oren M. (1989). INTERACTIONS BETWEEN SV40 AND CELLULAR ONCOGENES IN THE TRANSFORMATION OF PRIMARY RAT-CELLS.  Current Topics in Microbiology and Immunology. 144:63-75.

1988

32.
KRAISS S., QUAISER A., Oren M. & MONTENARH M. (1988). OLIGOMERIZATION OF ONCOPROTEIN-P53.  Journal of Virology. 62:(12)4737-4744.
31.
Amsterdam A., Zauberman A., Meir G., PINHASIKIMHI O., SUH B. & Oren M. (1988). COTRANSFECTION OF GRANULOSA-CELLS WITH SIMIAN VIRUS-40 AND HA-RAS ONCOGENE GENERATES STABLE LINES CAPABLE OF INDUCED STEROIDOGENESIS.  Proceedings of the National Academy of Sciences of the United States of America. 85:(20)7582-7586.
30.
Eliyahu D., Goldfinger N., PINHASIKIMHI O., SHAULSKY G., SKURNIK Y., ARAI N., Rotter V. & Oren M. (1988). METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES.  Oncogene. 3:(3)313-321.
29.
FINLAY C., HINDS P., TAN T., Eliyahu D., Oren M. & LEVINE A. (1988). ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE.  Molecular and Cellular Biology. 8:(2)531-539.
28.
Michalovitz (Michael) D., Pinhasi-Kimchi O., Eliyahu D., Ben-Ze'ev A. & Oren M. (1988). Complex Formation Between the p53 Cellular Tumor Antigen and Nuclear Heat Shock Proteins.  . 56:247-259.

1987

27.
MICHALOVITZ D., FISCHERFANTUZZI L., VESCO C., PIPAS J. & Oren M. (1987). Activated Ha-ras can cooperate with defective simian virus 40 in the transformation of nonestablished rat embryo fibroblasts.  Journal of Virology. 61:(8)2648-2654.  Abstract
26.
SHOHAT O., Greenberg M., REISMAN D., Oren M. & Rotter V. (1987). INHIBITION OF CELL-GROWTH MEDIATED BY PLASMIDS ENCODING P53 ANTISENSE.  Oncogene. 1:(3)277-283.

1986

25.
MICHALOVITZ D., Eliyahu D. & Oren M. (1986). Overproduction of protein p53 contributes to simian virus 40-mediated transformation.  Molecular and Cellular Biology. 6:(10)3531-3536.  Abstract
24.
PINHASIKIMHI O., MICHALOVITZ D., Ben-Ze'ev A. & Oren M. (1986). SPECIFIC INTERACTION BETWEEN THE P53 CELLULAR TUMOR-ANTIGEN AND MAJOR HEAT-SHOCK PROTEINS.  Nature. 320:(6058)182-185.
23.
KACZMAREK L., Oren M. & BASERGA R. (1986). COOPERATION BETWEEN THE P53 PROTEIN TUMOR-ANTIGEN AND PLATELET-POOR PLASMA IN THE INDUCTION OF CELLULAR DNA-SYNTHESIS.  Experimental Cell Research. 162:(1)268-272.
22.
MOAV B., HOROWITZ M., COHEN J., RECHAVI G., Eliyahu E., Oren M. & Givol D. (1986). STRUCTURE AND ACTIVITY OF THE TRANSLOCATED C-MYC IN MOUSE PLASMACYTOMA XRPC-24.  Gene. 48:(3-Feb)297-300.

1985

21.
Eliyahu D., Michalovitz D. & Oren M. (1985). Overproduction of p53 antigen makes established cells highly tumorigenic.  Nature. 316:(6024)158-160.  Abstract
20.
Oren M. (1985). THE P53 CELLULAR TUMOR-ANTIGEN - GENE STRUCTURE, EXPRESSION AND PROTEIN-PROPERTIES.  Biochimica Et Biophysica Acta. 823:(1)67-78.
19.
LEBEAU M., WESTBROOK C., DIAZ M., ROWLEY J. & Oren M. (1985). TRANSLOCATION OF THE P53 GENE IN TRANS-(15-17) IN ACUTE PROMYELOCYTIC LEUKEMIA.  Nature. 316:(6031)826-828.
18.
ZAKUTHOURI R., BIENZTADMOR B., Givol D. & Oren M. (1985). HUMAN P53 CELLULAR TUMOR-ANTIGEN - CDNA SEQUENCE AND EXPRESSION IN COS CELLS.  EMBO Journal. 4:(5)1251-1255.
17.
ROGEL A., Popliker M., WEBB C. & Oren M. (1985). P53 CELLULAR TUMOR-ANTIGEN - ANALYSIS OF MESSENGER-RNA LEVELS IN NORMAL ADULT TISSUES, EMBRYOS, AND TUMORS.  Molecular and Cellular Biology. 5:(10)2851-2855.
16.
BIENZTADMOR B., ZAKUTHOURI R., LIBRESCO S., Givol D. & Oren M. (1985). THE 5' REGION OF THE P53 GENE - EVOLUTIONARY CONSERVATION AND EVIDENCE FOR A NEGATIVE REGULATORY ELEMENT.  EMBO Journal. 4:(12)3209-3213.

1984

15.
PINHASI O. & Oren M. (1984). EXPRESSION OF THE MOUSE P53 CELLULAR TUMOR-ANTIGEN IN MONKEY CELLS.  Molecular and Cellular Biology. 4:(10)2180-2186.
14.
WOLF D., ADMON S., Oren M. & Rotter V. (1984). ABELSON MURINE LEUKEMIA VIRUS-TRANSFORMED CELLS THAT LACK P53 PROTEIN-SYNTHESIS EXPRESS ABERRANT P53 MESSENGER-RNA SPECIES.  Molecular and Cellular Biology. 4:(3)552-558.
13.
Eliyahu D., Raz A., GRUSS P., Givol D. & Oren M. (1984). PARTICIPATION OF P53 CELLULAR TUMOR-ANTIGEN IN TRANSFORMATION OF NORMAL EMBRYONIC-CELLS.  Nature. 312:(5995)646-649.
12.
BIENZ B., ZAKUTHOURI R., Givol D. & Oren M. (1984). ANALYSIS OF THE GENE CODING FOR THE MURINE CELLULAR TUMOR-ANTIGEN P53.  EMBO Journal. 3:(9)2179-2183.
11.
CZOSNEK H., BIENZ B., Givol D., ZAKUTHOURI R., PRAVTCHEVA D., RUDDLE F. & Oren M. (1984). THE GENE AND THE PSEUDOGENE FOR MOUSE P53 CELLULAR TUMOR-ANTIGEN ARE LOCATED ON DIFFERENT CHROMOSOMES.  Molecular and Cellular Biology. 4:(8)1638-1640.

1983

10.
Oren M., BIENZ B., Givol D., RECHAVI G. & ZAKUT R. (1983). ANALYSIS OF RECOMBINANT DNA CLONES SPECIFIC FOR THE MURINE-P53 CELLULAR TUMOR-ANTIGEN.  EMBO Journal. 2:(10)1633-1639.
9.
ZAKUTHOURI R., Oren M., BIENZ B., LAVIE V., HAZUM S. & Givol D. (1983). A SINGLE GENE AND A PSEUDOGENE FOR THE CELLULAR TUMOR ANTIGEN-P53.  Nature. 306:(5943)594-597.
8.
Oren M. & LEVINE A. (1983). MOLECULAR-CLONING OF A CDNA SPECIFIC FOR THE MURINE P53 CELLULAR TUMOR-ANTIGEN.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 80:(1)56-59.
7.
REICH N., Oren M. & LEVINE A. (1983). 2 DISTINCT MECHANISMS REGULATE THE LEVELS OF A CELLULAR TUMOR-ANTIGEN, P53.  Molecular and Cellular Biology. 3:(12)2143-2150.

1982

6.
GIDONI D., SCHELLER A., BARNET B., HANTZOPOULOS P., Oren M. & PRIVES C. (1982). DIFFERENT FORMS OF SIMIAN VIRUS-40 LARGE TUMOR-ANTIGEN VARYING IN THEIR AFFINITIES FOR DNA.  Journal of Virology. 42:(2)456-466.

1980

5.
Oren M., Winocour E. & PRIVES C. (1980). DIFFERENTIAL AFFINITIES OF SIMIAN VIRUS-40 LARGE TUMOR-ANTIGEN FOR DNA.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 77:(1)220-224.

1979

4.
PRIVES C., BECK Y., GIDONI D., Oren M. & SHURE H. (1979). DNA-BINDING AND SEDIMENTATION PROPERTIES OF SV40 T-ANTIGENS SYNTHESIZED INVIVO AND INVITRO.  Cold Spring Harbor Symposia on Quantitative Biology. 44:123-130.

1978

3.
Oren M., Lavi S. & Winocour E. (1978). STRUCTURE OF A CLONED SUBSTITUTED SV40-GENOME.  Virology. 85:(2)404-421.

1977

2.
GLUZMAN Y., DAVISON J., Oren M. & Winocour E. (1977). PROPERTIES OF PERMISSIVE MONKEY CELLS TRANSFORMED BY UV-IRRADIATED SIMIAN VIRUS-40.  Journal of Virology. 22:(2)256-266.

1976

1.
Oren M., KUFF E. & Winocour E. (1976). PRESENCE OF COMMON HOST SEQUENCES IN DIFFERENT POPULATIONS OF SUBSTITUTED SV40-DNA.  Virology. 73:(2)419-430.